Rare & Genetic Diseases
| 2 min read
In a deal between Adherex and GlaxoSmithKline (GSK) penned in July, Adherex received an exclusive license to the oncology product eniluracil for all indications, while GSK gained an option to license Adherex’s lead biotechnology compound, ADH-1.
